Trial record 2 of 5 for:
Alzheimer AND Fyn
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02167256 |
|
Recruitment Status :
Completed
First Posted : June 19, 2014
Results First Posted : August 14, 2019
Last Update Posted : August 14, 2019
|
Sponsor:
Yale University
Collaborator:
Alzheimer's Therapeutic Research Institute
Information provided by (Responsible Party):
Stephen M. Strittmatter, Yale University
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2. Moreover, the investigators have recently shown that a specific SFK, namely Fyn, is aberrantly activated by specific conformations of the Amyloid Beta (Aß) peptide from Alzheimer's disease (AD). Genetic deletion of Fyn rescues AD deficits in preclinical models. This clinical trial will test the potential benefit of AZD0530 for Alzheimer's disease modification.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alzheimer's Disease | Drug: AZD0530 100mg daily Drug: AZD0530 125mg daily Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 159 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease |
| Actual Study Start Date : | December 2014 |
| Actual Primary Completion Date : | February 27, 2018 |
| Actual Study Completion Date : | February 27, 2018 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Alzheimer disease
MedlinePlus related topics:
Alzheimer's Disease
| Arm | Intervention/treatment |
|---|---|
|
Experimental: AZD0530 100mg daily
Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of <100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.
|
Drug: AZD0530 100mg daily
All patients in experimental group (50%) will be started on 100mg AZD0530 daily
Other Name: saracatinib Drug: AZD0530 125mg daily Patients with plasma drug level <100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
Other Name: saracatinib |
|
Placebo Comparator: AZD0530 Placebo
50% of patients will receive placebo treatment for the duration of the study,
|
Drug: Placebo
50% of patients will receive placebo treatment for the duration of the study.
Other Name: saracatinib |
Primary Outcome Measures :
- Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging [ Time Frame: 12 months ]Composite measure of brain glucose uptake using F18-FDG PET in a pre-defined set of brain regions, between baseline and 12 months.
- Number of Participants With One or More Serious/Other Adverse Events Subjects With Mild AD as Assessed by Analysis of Adverse Events, Including Symptoms, and Abnormal Findings on Physical and Neurological Examinations, and Standard Labs. [ Time Frame: 12 months ]Assessment of any adverse effects between drug and placebo-treated subjects
Secondary Outcome Measures :
- The Effect of Treatment With AZD0530 on Cognitive and Behavioral Function [ Time Frame: 12 months ]
The change in cognitive function between baseline and 12 months will be measured by the following tests:
- Alzheimer Disease Assessment Scale - Cognitive 11 (ADAS-cog11). Measures: Cognitive function Maximum score: 70; Minimum score: 0. Higher score equals worse cognitive function
- Mini-Mental State Examination (MMSE) Measures: Cognitive Function Maximum score: 30; Minimum score: 0. Higher score equal better cognitive function
- Alzheimer Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Measures: Ability to perform routine daily activities Maximum score: 78; Minimum score: 0. Higher score equals better ability to perform activities of daily living
- Clinical Dementia Rating Sum of Boxes (CDR-SO) Measures: Dementia severity Maximum score: 18; Minimum score: 0. Higher score equals more severe dementia.
- Percent Change in Brain Volume Before and After Treatment [ Time Frame: 12 months ]Change in volume of pre-defined brain regions between baseline and 12 months of treatment.
- Cerebrospinal Fluid Levels of Total Tau, Phospho-tau (p-Tau), and Amyloid-beta 1-42 (Abeta 1-42) [ Time Frame: 12 months ]Measure concentration of Tau and Amyloid-beta 1-42 biomarkers in the cerebrospinal fluid between baseline and 12 months of treatment
- Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging [ Time Frame: 12 months ]The results from the primary outcome with brain FDG-PET imaging was analyzed by ApoE genotype. Composite measure of brain glucose uptake using F18-FDG PET in a pre-defined set of brain regions, between baseline and 12 months.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 55 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria
- NIA-Alzheimer's Association core clinical criteria for probable AD
- 18F-Florbetapir scan with evidence of elevated Aβ (based on central review)
- Age between 55-85 (inclusive)
- MMSE score between 18 and 26 (inclusive)
-
Stability of permitted medications for 4 weeks. In particular:
- Stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past 1 year)
- Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to screen
- Geriatric Depression Scale less than 6 [Note: a score ≥6 on this screening scale may be permissible, if the subject is examined by a site clinician and judged not to be depressed.]
- Study partner is available who has frequent contact with the subject (e.g., average of 10 hours per week or more), and can accompany the subject to most visits to answer questions about the subject
- Visual and auditory acuity adequate for neuropsychological testing
- Good general health with no disease expected to interfere with the study
- Subject is not pregnant, lactating, or of childbearing potential (i.e., women must be two years post-menopausal or surgically sterile)
- Modified Hachinski less than or equal to 4
- Completed six grades of education or has a good work history
- Must speak English or Spanish fluently
Exclusion Criteria
- Any significant neurologic disease other than AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities
- Screening/baseline MRI scan with evidence of infection, infarction, or other focal lesions or multiple lacunes or lacunes in a critical memory structure
- Subjects that have any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or cardiac pacemaker
- Major depression, bipolar disorder as described in DSM-IV within the past 1 year or psychotic features, agitation or behavioral problems within 3 months, which could lead to difficulty complying with the protocol
- History of schizophrenia (DSM V criteria)
- History of alcohol or substance abuse or dependence within the past 2 years (DSM V criteria)
- Clinically significant or unstable medical condition, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic disease in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results, or the subject's ability to participate in the study.
- Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen post-treatment
- Clinically significant abnormalities in B12 or TFTs that might interfere with the study. A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant.
- Residence in skilled nursing facility.
- Use of any excluded medication as described in study protocol
- Current or recent participation in any procedures involving radioactive agents, including current, past, or anticipated exposure to radiation in the workplace, such that the total radiation dose exposure to the subject in a given year would exceed the limits of annual and total dose commitment set forth in the US Code of Federal Regulations (CFR) Title 21 Section 361.1. This guideline is an effective dose of 5 rem received per year.
- Neutropenia defined as absolute neutrophils count of <1,800/microliter
- Thrombocytopenia defined as platelet count <120x103/microliter
- For CSF sub-study participants, a current blood clotting or bleeding disorder, or significantly abnormal PT or PTT at screening
-
Clinically significant abnormalities in screening laboratories, including:
- Aspartate aminotransferase (AST) >1.5 times ULN
- Alanine aminotransferase (ALT) > 1.5 times ULN
- Total bilirubin >1.5 times ULN
- Serum creatinine >2.0 times ULN
- History of interstitial lung disease
- Patients whom the PI deems to be otherwise ineligible
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02167256
Locations
Show 22 study locations
Sponsors and Collaborators
Yale University
Alzheimer's Therapeutic Research Institute
Investigators
| Study Director: | Christopher H van Dyck, MD | Yale University | |
| Study Director: | Paul Aisen, MD, PhD | USC Alzheimer's Therapeutic Research Institute (ATRI) |
Study Documents (Full-Text)
Documents provided by Stephen M. Strittmatter, Yale University:
Documents provided by Stephen M. Strittmatter, Yale University:
Study Protocol and Statistical Analysis Plan [PDF] May 31, 2017
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Stephen M. Strittmatter, Professor of Neurology and Neurobiology, Yale University |
| ClinicalTrials.gov Identifier: | NCT02167256 |
| Other Study ID Numbers: |
1404013830 4UH3TR000967-02 ( U.S. NIH Grant/Contract ) |
| First Posted: | June 19, 2014 Key Record Dates |
| Results First Posted: | August 14, 2019 |
| Last Update Posted: | August 14, 2019 |
| Last Verified: | July 2019 |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases |
Neurocognitive Disorders Mental Disorders Saracatinib Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |